<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03229876</url>
  </required_header>
  <id_info>
    <org_study_id>2018CAR-00CH1</org_study_id>
    <nct_id>NCT03229876</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Evaluation of CD19-UCART</brief_title>
  <official_title>A Safety and Efficacy Study of CD19-UCART (Allogeneic Engineered T-cells Expressing Anti-CD19 Chimeric Antigen Receptor) in Patients With Relapsed or Refractory B-cell Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioray Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bioray Laboratories</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of ascending doses of&#xD;
      CD19-UCART in patients with relapsed or refractory B-cell hematological malignancies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CD19-UCART is a kind of &quot;off-the-shelf&quot; product originated from health donor's PBMC.This is a&#xD;
      open-label, dose estilation study to evaluate the safety and anti-tumor efficacy of&#xD;
      CD19-UCART in the treatment of relapsed or refractory B-cell hematological malignancies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicities (DLTs) occurence</measure>
    <time_frame>Baseline up to 35 days after T cell infusion</time_frame>
    <description>Adverse events assessed according to NCI-CTCAE v4.03 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>At 12 weeks, and overall</time_frame>
    <description>Proportion of patients in whom a response among complete response and partial response as defined by standard disease-specific criteria, will be observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence of CART cells</measure>
    <time_frame>Assessed up to 3 months</time_frame>
    <description>Duration of persistence of CD19-UCART cells after infusion will be detected by FACS or QPCR</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Acute Lymphoblastic Leukemia (ALL)</condition>
  <condition>Non Hodgkin Lymphoma (NHL)</condition>
  <arm_group>
    <arm_group_label>CD19-UCART</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will be treated with 1 injection of CD19-UCART. Three escalating dose-levels (5x10^6/kgBW, 7x10^6/kgBW, 10x10^6/kgBW) of CD19-UCART will be evaluated using a 3+3 design. Each CD19-UCART injection will be administered at Day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CD19-UCART</intervention_name>
    <description>A conditioning therapy with cyclophosphamide and fludarabine will be conducted before CD19-UCART injection. VP16 can be added to the conditioning therapy.</description>
    <arm_group_label>CD19-UCART</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Previously confirmed diagnosis as CD19+ ALL or NHL within18 months;&#xD;
&#xD;
          2. ALL patients with the age between 6 and 30;or NHL patients between 16 and 65;&#xD;
&#xD;
          3. Relapsed or refractory B-ALL or NHL;&#xD;
&#xD;
          4. Expected survival &gt;4W;&#xD;
&#xD;
          5. ECOG &lt;2;&#xD;
&#xD;
          6. Have the capacity to give informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating women;&#xD;
&#xD;
          2. Isolated extramedullary relapse of ALL;&#xD;
&#xD;
          3. Severe mental disorders, active autoimmune diseases, active infectious diseases,&#xD;
             severe cardiovascular diseases;&#xD;
&#xD;
          4. With other type of maligant tumors in the past;&#xD;
&#xD;
          5. Acceptance of allogeneic stem cell transplant (ASCT);&#xD;
&#xD;
          6. Any circumstances that possibly increase the risk of subjects or interfere with study&#xD;
             results, which judged by investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi Zhang, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affliated Hospital of Zhengzhou University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>He Huang, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affliated Hospital of Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wei Li, phD</last_name>
    <phone>+8602164340008</phone>
    <email>wli@bioraylab.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>First Affliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinfeng Chen, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Yi Zhang, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Affliated Hospital of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongxian Hu, Prof</last_name>
      <phone>+8615957162012</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 19, 2017</study_first_submitted>
  <study_first_submitted_qc>July 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2017</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

